UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection
UK chief medical officers to confirm how antibody cocktails will be rolled out on the National Health Service (NHS) in the coming weeks.
In the U.S., Regeneron has completed the first FDA BLA submission for the antibody cocktail; more than 130,000 doses were distributed in the past week to address COVID-19 outbreaks.
(STL.News) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the United Kingdom’s (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted Conditional Marketing Authorization (CMA) for the casirivimab and imdevimab antibody cocktail, known as REGEN-COV™ in the U.S. and Ronapreve® in the UK and other countries, to prevent and treat acute COVID-19 infection. In addition to the CMA, which affects people in England, Scotland and Wales, the MHRA has also authorized emergency supply of the antibody cocktail to prevent and treat acute COVID-19 infection for people in Northern Ireland.
“Despite the remarkable collective efforts of governments, healthcare professionals, and communities across the globe, COVID-19 continues to cause significant illness and death, with new variants making the fight even more challenging,” said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron.